Informa Connect Life Sciences’ Post

At Nomisma Healthcare PVT. LTD. we are proud to be at the forefront of biomedical innovation, manufacturing high-quality PEG-PLGA Block Copolymers. These advanced materials combine PEG’s hydrophilicity with PLGA’s biodegradability, making them a game-changer in various medical applications. 🔬 Key Applications: - Drug Delivery Systems: Ideal for formulating nanoparticles, micelles, and hydrogels for controlled and targeted drug delivery. - Tissue Engineering: Essential in developing scaffolds for tissue repair and regeneration. - Medical Devices: Used in the creation of bioresorbable implants, stents, and sutures. - Cancer Therapy: Designed for nanocarriers that deliver chemotherapeutic agents directly to tumor sites. Transform your research and product development with our PEG-PLGA Block Copolymers. Reach out to us at info@nomismahealthcare.com to learn more or to place an order. #NomismaHealthcare #Biopolymers #DrugDelivery #TissueEngineering #MedicalDevices #CancerTherapy #Innovation

📣 Follow our monthly focus on groundbreaking nanobody-exosome research and enjoy up to 30% off on a wide range of exosome products and customizable solutions 📢 Exciting news! Read our blog post on the revolutionary potential of #exosomes in therapy. Discover how our exosome solutions and #nanobody products are shaping #biomedicalresearch: https://lnkd.in/gcjHA8Za Follow us for more updates! #ExosomeResearch #TherapeuticAdvancements

𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐒𝐭𝐮𝐝𝐲 𝐰𝐢𝐭𝐡 𝐟𝐨𝐜𝐮𝐬 𝐨𝐧 𝐤𝐞𝐲 𝐝𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐭𝐫𝐞𝐧𝐝𝐬 𝐀𝐬𝐤 𝐎𝐮𝐫 𝐄𝐱𝐩𝐞𝐫𝐭𝐬 👉👉 https://lnkd.in/dSpyvQTw  𝐓𝐡𝐞 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 40.64 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2030, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 6.20% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝. Solid tumor detection refers to the identification and localization of abnormal masses or growths in the body that are characterized by a solid, compact structure rather than a liquid or cystic one. Tumors can be either benign (non-cancerous) or malignant (cancerous), and they can develop in various tissues and organs. Solid tumor detection is a crucial aspect of medical diagnostics, as early identification and accurate localization of tumors play a key role in the diagnosis and treatment of cancer. Agilent Technologies, Becton Dickinson Company (Safety Syringes, Inc. ), Danaher Corporation, F. Hoffmann-La Roche Ltd, Illumina & Thermo Fisher Scientific 𝐁𝐨𝐨𝐤 𝐎𝐮𝐫 𝐋𝐚𝐭𝐞𝐬𝐭 𝐄𝐝𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 👉👉 https://lnkd.in/d2cMzR-W  HTF Market Intelligence Consulting Pvt Ltd DKS Global Research #tumordetection #solidtumors #detection #tumor #solidtumordetectionmarket #solidtumordetection

𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐓𝐢𝐬𝐬𝐮𝐞 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐒𝐞𝐭 𝐟𝐨𝐫 𝐑𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐆𝐫𝐨𝐰𝐭𝐡 Download PDF Brochure: https://lnkd.in/dSjg8ACc Exciting developments in the cardiac tissue engineering market reveal promising trajectories! New market analysis shows the sector valued at $621.2M in 2024 is poised to reach $1.33B by 2029, demonstrating a robust CAGR of 16.5%. Key Growth Drivers: • Expanding demand for regenerative medicine solutions • Rising cardiovascular disease incidents globally • Breakthrough developments in stem cell research Market Segments: • Materials: Advanced scaffolds and stem cell technologies • Products: Heart valves and vascular grafts • Applications: Myocardial infarction and congenital heart disease • End-Users: Leading hospitals, clinics, and research institutions 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Terumo Medical Corporation, Artivion, Inc., Baxter International Inc., Teijin Limited, Medtronic, Boston Scientific, Abbott, Merck KGaA, Darmstadt, Germany, Elutia, W. L. Gore & Associates, Meril, FUJIFILM Holdings Corporation, Vascudyne Inc, BICO, REPROCELL, PromoCell, Axol Bioscience Ltd., BPS Bioscience Inc., Cell Application, Inc. (US), Viscofan DE GmbH #HealthcareInnovation #BiotechMarket #CardiacCare #RegenerativeMedicine #MarketResearch #MedTech #Healthcare #Innovation #BioTechnology

With the rapid growth of cell and gene-modified cell therapies, overcoming clinical, manufacturing, and commercialization setbacks are crucial to success. Download our whitepaper to learn how to enhance your knowledge for the advancement of regenerative medicine. https://okt.to/47uxwC #celltherapy #genemodified #advancedtherapies

Congratulations to convEyXO on being the latest addition to the "Global Database of Exosome Companies, 2024": https://lnkd.in/ezHg2Pc ConvEyXO, a Belgian biotech company, targets inflammatory and degenerative diseases with unmet medical needs by reducing inflammation and repairing tissue damages from cellular senescence with its Therapeutic Platform based on small Extracellular Vesicles (sEV or exosomes) secreted by Mesenchymal Stem Cells (MSCs), with their intrinsic immuno-modulatory and regenerative properties, amplified by loaded miRNA. ConvEyXO resolves sEV industrialization key challenges with a proprietary Technology Platform, making their therapies triple A with (1) homogenous industrial manufacturing from single cell line sourcing, with robust isolation, purification and characterization processes, (2) cost-efficient scalable production with patented process and proprietary 3D custom fixed-bed bioreactor and (3) Amplified sEV native properties by loading miRNA with a breakthrough microfluidic technology. #exosomes #extracellularvesicles #advancedtherapies Frédéric Tonglet

Sarcomatrix is on the brink of revolutionizing the treatment landscape for Duchenne Muscular Dystrophy (DMD), a field currently dominated by therapies that only postpone the inevitable progression of the disease. With the DMD market poised to reach a staggering $2 billion, our groundbreaking therapeutics promise not just to participate but to redefine the arena. Our timing couldn't have been better. By 2030, the global market for DMD treatments is expected to explode to $18 billion, with DMD constituting a significant 25% of all muscular dystrophy cases. This represents not just a healthcare challenge but a substantial economic opportunity for innovations that can alter the course of this devastating disease.

Congratulations to convEyXO on being the latest addition to the "Global Database of Exosome Companies, 2024": https://lnkd.in/g8VVNaHr ConvEyXO, a Belgian biotech company, targets inflammatory and degenerative diseases with unmet medical needs by reducing inflammation and repairing tissue damages from cellular senescence with its Therapeutic Platform based on small Extracellular Vesicles (sEV or exosomes) secreted by Mesenchymal Stem Cells (MSCs), with their intrinsic immuno-modulatory and regenerative properties, amplified by loaded miRNA. ConvEyXO resolves sEV industrialization key challenges with a proprietary Technology Platform, making their therapies triple A with (1) homogenous industrial manufacturing from single cell line sourcing, with robust isolation, purification and characterization processes, (2) cost-efficient scalable production with patented process and proprietary 3D custom fixed-bed bioreactor and (3) Amplified sEV native properties by loading miRNA with a breakthrough microfluidic technology. #exosomes #extracellularvesicles #advancedtherapies Frédéric Tonglet

ZHUHAI DL Biotech CO., Ltd. (NEEQ: 873831) has officially launched its new DL-EXO-S Serum Exosome Isolation Reagent. This cutting-edge product uses a serum exosome precipitation method that is both cost-effective and straightforward, allowing researchers to isolate exosomes from blood samples within just two hours. This efficiency offers a significant advantage in biomedical research by providing a streamlined and reliable exosome isolation solution. Exosomes, small vesicles ranging from 30-150 nm, are crucial for cell communication and signaling. They contain various biomolecules, including proteins, lipids, and RNA, and play a vital role in disease diagnostics, particularly in the early detection of cancers. #ExosomeResearch #BiomedicalInnovation #ClinicalResearch #ExosomeIsolation #Biotech #EarlyDiagnostics #CancerResearch #QimingPortfolio #QimingHealthcare

With the rapid growth of cell and gene-modified cell therapies, overcoming clinical, manufacturing, and commercialization setbacks are crucial to success. Download our whitepaper to learn how to enhance your knowledge for the advancement of regenerative medicine. https://okt.to/48A5q0 #celltherapy #genemodified #advancedtherapies